Abandonment or Reversion. In the event of an “Abandonment” or a “Reversion”, each as defined in [Article II] of the Operations Agreement, this Agreement will terminate automatically on the earlier of # the effective date of PTG’s Notice of Reversion or # forty-five days after the effective date of Healthtech’s Notice of Abandonment.

Abandonment or Reversion. In the event of an “Abandonment” or a “Reversion”, each as defined in [Section II] of the Operations Agreement, this Agreement will terminate automatically on the earlier of # the effective date of PTG’s Notice of Reversion or # forty-five days after the effective date of Healthtech’s Notice of Abandonment.

Abandonment. Abandonment or vacation of the Premises for a continuous period in excess of five (5) days. Tenant waives any right to notice Tenant may have under Section 1951.3 of the Civil Code of the State of California, the terms of this Paragraph 27.1 being deemed such notice to Tenant as required by said [Section 1951.3].

Abandonment. Tenant shall abandon the Premises.

Abandonment. Tenant shall abandon the Premises. Tenant shall not be deemed to have abandoned the Premises if Tenant provides Landlord with reasonable advance notice prior to vacating and, at the time of vacating the Premises, # Tenant completes Tenant’s obligations under the Surrender Plan in compliance with [Section 28]. # Tenant has obtained the release of the Premises of all Hazardous Materials Clearances and the Premises are free from any residual impact from the Tenant HazMat Operations and provides reasonably detailed documentation to Landlord confirming such matters, # Tenant has made reasonable arrangements with Landlord for the security of the Premises for the balance of the Term, and # Tenant continues during the balance of the Term to satisfy and perform all of Tenant’s obligations under this Lease as they come due.

Abandonment. Merck shall promptly give notice to Licensee of the grant lapse, revocation, surrender, invalidation or abandonment of any Compound Patent Rights licensed to Licensee for which Merck is responsible for the prosecution and maintenance under this Agreement.

Reversion. At no time, prior to the satisfaction of all liabilities with respect to Participants and their beneficiaries, shall any part of the assets of the Plan be used for or diverted to purposes other than for the exclusive benefit of such persons; provided, however, Employer contributions may be returned to the Employer # if made by the Employer by a mistake of fact, within one year after the payment of the contribution, or # if a contribution is conditioned upon the deductibility of such contribution under Code Section 404, then to the extent the deduction is disallowed, within one year of the disallowance of the deduction. The amount of any contribution that may be returned to the Employer must be reduced by any portion thereof previously distributed from the Trust Fund and by any losses of the Trust Fund allocable thereto, and in no event may the return of such contribution cause any Participant’s Account balances to be less than the amount of such balances had the contribution not been made under the Plan.

Reversion. Upon receipt of notice of Abandonment by HLTT and at any time during the sixty (60) days following receipt of such notice, PTG may give HLTT written notice that it will make a good faith effort to assist HWC in achieving financial success, which notice shall be accompanied by a budget for the effort and an identification of sources of financing. Upon HLTT’s receipt of that notice with the requisite information, a “Reversion” shall be implemented. HLTT shall transfer to PTG managerial control of HWC, and PTG shall implement its commitment to a good faith effort. If within three years after commencement of

If the Parties agree on such payment obligations for such Reversion Product during such ​ negotiation period, then the Parties will memorialize such payment obligations for such Reversion Product in a definitive agreement.

Termination. On a Reversion Product-by-Reversion Product basis, # the Opt-Out Party will have the right to terminate this Agreement) in accordance with [[Sections 16.3(a)(i), 16.3(a)(ii) and 16.3(a)(iii)])])]])] (but, for clarity, not [Section 16.3(a)(iv)]) with respect to the applicable Reversion Product, and # the Continuing Party will have the right to terminate this Agreement upon written notice to the Opt-Out Party of the Continuing Party’s decision, its sole discretion, to cease permanently the Research, Development and Commercialization of such Reversion Product (which notice will be provided within ​ of the Continuing Party making such decision). In the event of a termination of this Agreement with respect to a Reversion Product, then the consequences in [Section 16.5(b)] will apply. For clarity, any termination of this Agreement with respect to a Reversion Product will result in the termination of the applicable Collaboration Antigen.